Beneficial effects of synthetic KL4-surfactant in experimental lung transplantation.
Summary of "Beneficial effects of synthetic KL4-surfactant in experimental lung transplantation."
The aim of this study was to investigate whether intratracheal administration of a new synthetic surfactant that includes the cationic, hydrophobic 21-residue peptide KLLLLKLLLLKLLLLKLLLLK (KL4), might be effective in reducing ischemia-reperfusion injury after lung transplantation. Single left lung transplantation was performed in Landrace pigs 22 hours post harvest. KL4-surfactant at a dose of 25 mg (2.5 mL)/kg total phospholipid was instilled at 37 degrees C to the donor left lung (n=8) prior to explantation. Saline (2.5 mL.kg(-1); 37 degrees C) was instilled into the donor left lung of the untreated group (n=6). Lung function in recipients was measured during 2 hr of reperfusion. Recipient left lung bronchoalveolar lavage (BAL) provided native cytometric, inflammatory marker, and surfactant data. KL4-surfactant treatment recovered oxygen levels in the recipient blood (Pa,O2/FiO2 of 424+/-60 mm Hg vs. 263+/-101 mm Hg in untreated group; p=0.01) and normalized alveolar-arterial oxygen gradient. Surfactant biophysical function was also recovered in KL4-surfactant-treated lungs. This was associated with decreased C-reactive protein levels in BAL and recovery of surfactant protein A content, normalized protein/phospholipid ratios, and lower levels of both lipid peroxides and protein carbonyls in large surfactant aggregates. These findings suggest an important protective role for KL4-surfactant treatment in lung transplantation.
Affiliation
Complutense University and CIBERES (Respiratory Research Center) Madrid Spain.
Journal Details
This article was published in the following journal.
Name: The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology
ISSN: 1399-3003
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20650990
- DOI: http://dx.doi.org/10.1183/09031936.00020810
Medical and Biotech [MESH] Definitions
Pulmonary Surfactant-associated Protein D
An abundant pulmonary surfactant-associated protein that binds to a variety of lung pathogens and enhances their opsinization and killing by phagocytic cells. Surfactant protein D contains a N-terminal collagen-like domain and a C-terminal lectin domain that are characteristic of members of the collectin family of proteins.
Pulmonary Surfactant-associated Protein A
An abundant pulmonary surfactant-associated protein that binds to a variety of lung pathogens, resulting in their opsinization. It also stimulates MACROPHAGES to undergo PHAGOCYTOSIS of microorganisms. Surfactant protein A contains a N-terminal collagen-like domain and a C-terminal lectin domain that are characteristic of members of the collectin family of proteins.
Neoplasm Transplantation
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Pulmonary Surfactant-associated Protein C
A pulmonary surfactant associated protein that plays a role in alveolar stability by lowering the surface tension at the air-liquid interface. It is a membrane-bound protein that constitutes 1-2% of the pulmonary surfactant mass. Pulmonary surfactant-associated protein C is one of the most hydrophobic peptides yet isolated and contains an alpha-helical domain with a central poly-valine segment that binds to phospholipid bilayers.
Pulmonary Surfactant-associated Protein B
A pulmonary surfactant associated-protein that plays an essential role in alveolar stability by lowering the surface tension at the air-liquid interface. Inherited deficiency of pulmonary surfactant-associated protein B is one cause of RESPIRATORY DISTRESS SYNDROME, NEWBORN.
PubMed Articles
Aspiration pneumonitis, a direct cause of acute lung injury, is associated to a severe deterioration of lung function due in part to endogenous surfactant system impairment. We evaluated the effects o...
Surfactant protein A (SP-A) is the most abundant protein component of lung surfactant, a complex mixture of proteins and lipids. SP-A performs host defense activities and modulates the biophysical pro...
ABSTRACT: INTRODUCTION: Previous randomized trials failed to demonstrate a decrease in mortality of patients with acute lung injury treated by exogenous surfactant. The aim of this prospective randomi...
Abstract Objective: Recent ultrasonographic studies suggest that the administration of surfactant to preterm infants with respiratory distress syndrome (RDS) does not affect lung water clearance. The...
Pulmonary hypertension before first and second lung transplantation.
Tonelli AR, Timofte I, Minai OA, Baz M, Akindipe O. Pulmonary hypertension before first and second lung transplantation. Clin Transplant 2012 DOI: 10.1111/j.1399-0012.2011.01588.x. © 2012 John Wiley...
Clinical Trials
The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study
1. Working Hypothesis: The purpose of the trial is to study the effect of exogenous calf surfactant (calfactant) on the prevention of primary graft failure due to ischemic-reper...
Human Surfactant Treatment of Respiratory Distress Syndrome Bicenter Trial
To determine if surfactant administration at birth in infants at high risk for respiratory distress syndrome (RDS) modified the clinical course of the syndrome.
Impact of Surfactant's Availability on Newborns
To identify what happened to specific groups of newborns after surfactant was introduced to the market. Were the same benefits with regard to morbidity, mortality, and resource use in evid...
Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration
The objective of this pilot study is to examine the feasibility and safety of performing a larger trial to assess outcomes following treatment of meconium aspiration syndrome with surfacta...
Genetic Regulation of Surfactant Deficiency
Inherited deficiencies in any one of 3 genes (surfactant protein B, surfactant protein C, and ATP-binding cassette transporter A3) can cause neonatal respiratory distress syndrome by disru...
